贝达药业 reported revenue of ¥1.98B for the period ended 2026-06-30, +14.1% year on year. Net income was ¥0.29B, a 14.8% net margin on a 76.4% gross margin. The largest revenue line is 药品销售 at 99% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.98B | +14.1% |
| Gross profit | ¥1.51B | — |
| Operating income | ¥0.37B | — |
| Net income | ¥0.29B | +123.9% |
| Gross margin | 76.4% | Net margin 14.8% |
| Revenue Q/Q | -10.0% | — |
| Segment | Revenue | Share |
|---|---|---|
| 药品销售 | ¥1.96B | 99.4% |
| 其他(补充) | ¥0.01B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.47B | 23.6% |
| R&D | ¥0.22B | 11.0% |
| SG&A | ¥0.89B | 45.0% |
| Tax & other | ¥0.08B | 3.9% |
| Item | Amount |
|---|---|
| Total assets | ¥10.30B |
| Total liabilities | ¥3.66B |
| Shareholders' equity | ¥6.64B |
| Equity / assets | 64.4% |
| Operating cash flow | ¥0.15B |
| Capital expenditure | ¥0.03B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 141% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
佳发教育 ・ 中富通 ・ 汇金科技 ・ 乐心医疗 ・ 神宇股份 ・ 筑博设计 ・ 科信技术 ・ 激智科技 ・ 精测电子 ・ 星源材质 ・ 天能重工 ・ 太辰光
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies